FDA Approves Merck’s Pneumococcal Vaccine for Adults
The vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older.
The vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older.
New research has found that influenza-like illness can lead to pneumococcal colonization of airways that may persist after recovery.